JOP20200114A1 - عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون - Google Patents

عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون

Info

Publication number
JOP20200114A1
JOP20200114A1 JOP/2020/0114A JOP20200114A JOP20200114A1 JO P20200114 A1 JOP20200114 A1 JO P20200114A1 JO P20200114 A JOP20200114 A JO P20200114A JO P20200114 A1 JOP20200114 A1 JO P20200114A1
Authority
JO
Jordan
Prior art keywords
substituent
compounds
disease
treatment
parkinson
Prior art date
Application number
JOP/2020/0114A
Other languages
English (en)
Inventor
Jorgensen Morten
Martin Juhl
Klaus Gjervig Jensen
Lisbet Kvaerno
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20200114A1 publication Critical patent/JOP20200114A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يُقدم الاختراع الحالي مركبات الصيغة (I) وهي عبارة عن عقاقير أولية من الكاتيكولامين للاستخدام في علاج اضطرابات وأمراض التنكس العصبي. يُقدم الاختراع الحالي تركيبات صيدلانية تشمل مركبات الاختراع و طرق لعلاج الإضطرابات والأمراض العصبية النفسية أو التنكس العصبي باستخدام مركبات الاختراع، وبشكل خاص مرض باركنسون. وفقًا لذلك، يتعلق الاختراع الحالي بمركبات الصيغة (Id) (Id) حيث R1 عبارة عن H و R2 يتم اختيارها من واحدة من المستبدلات (i) و (ii) المذكورة أدناه؛ أو R1 يتم اختيارها من واحدة من المستبدلات (i) و (ii) المذكورة أدناه و R2 عبارة عن H؛ أو R1 و R2 يتم تمثيل كل منهما بواسطة مستبدل (i) أدناه؛ أو R1 و R2 يتم تمثيل كل منهما بواسطة مستبدل (ii) أدناه؛ أو R1 عبارة عن مستبدل (i) و R2 عبارة عن مستبدل (ii)؛ أو R1 عبارة عن مستبدل (ii) و(R2) عبارة عن مستبدل (i)؛ (i) (ii) حيث * تشير إلى نقطة الارتباط؛ و حيث تكون ذرة الكربون عند نقطة الارتباط على مستبدل (i) في التكوين-S؛ أو ملح منه مقبول صيدليًا.
JOP/2020/0114A 2017-11-24 2018-11-23 عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون JOP20200114A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24
PCT/EP2018/082361 WO2019101917A1 (en) 2017-11-24 2018-11-23 New catecholamine prodrugs for use in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
JOP20200114A1 true JOP20200114A1 (ar) 2020-05-17

Family

ID=64661284

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0114A JOP20200114A1 (ar) 2017-11-24 2018-11-23 عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون

Country Status (25)

Country Link
US (4) US10729710B2 (ar)
EP (1) EP3713933A1 (ar)
JP (4) JP7320507B2 (ar)
KR (1) KR20200092955A (ar)
CN (3) CN117599073A (ar)
AR (1) AR113908A1 (ar)
AU (2) AU2018371193B2 (ar)
BR (1) BR112019014981A2 (ar)
CA (1) CA3082757A1 (ar)
CL (1) CL2020001343A1 (ar)
CO (1) CO2020006224A2 (ar)
CR (1) CR20200225A (ar)
EA (1) EA202090987A8 (ar)
EC (1) ECSP20030074A (ar)
GE (1) GEP20227446B (ar)
IL (1) IL274648A (ar)
JO (1) JOP20200114A1 (ar)
MA (1) MA50800A (ar)
MX (2) MX2020005366A (ar)
PE (1) PE20211290A1 (ar)
PH (1) PH12020550631A1 (ar)
SG (1) SG11202004461YA (ar)
TW (1) TWI816716B (ar)
UA (1) UA127575C2 (ar)
WO (1) WO2019101917A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200225A (es) * 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) * 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP2022533311A (ja) 2019-05-21 2022-07-22 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113727974A (zh) * 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023208869A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
WO2023208865A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
LU88619I2 (fr) 1981-10-16 1995-07-10 Sandoz Ag QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
PH22782A (en) 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
EP0393781B1 (en) 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine pro-drug
WO1990012574A1 (en) 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
AU2001255818A1 (en) 2000-04-07 2001-10-23 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
AU2001288242B2 (en) 2000-08-11 2005-11-17 Purdue Research Foundation Process for the preparation of dinapsoline
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
ATE365040T1 (de) 2001-08-10 2007-07-15 Purdue Research Foundation Chirales dinapsolin
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
AU2003223304A1 (en) 2002-03-19 2003-10-08 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
JP2007516292A (ja) 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
WO2006012640A2 (en) 2004-07-21 2006-02-02 Darpharma, Inc. Method of administration of dopamine receptor agonists
WO2006056604A1 (en) 2004-11-25 2006-06-01 Evolva Ag Levodopa glycosyl derivatives, methods of preparation and use
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
EP2557079A1 (en) 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
US20190224220A1 (en) 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
CR20200225A (es) * 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2022533311A (ja) 2019-05-21 2022-07-22 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113727974A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP2023013012A (ja) * 2021-07-15 2023-01-26 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
JP2023145579A (ja) 2023-10-11
CA3082757A1 (en) 2019-05-31
AR113908A1 (es) 2020-06-24
MA50800A (fr) 2020-09-30
ECSP20030074A (es) 2020-07-31
CN117599073A (zh) 2024-02-27
AU2023201741A1 (en) 2023-04-20
US20240156851A1 (en) 2024-05-16
GEP20227446B (en) 2022-12-12
CR20200225A (es) 2020-07-25
WO2019101917A1 (en) 2019-05-31
TWI816716B (zh) 2023-10-01
CN111386267A (zh) 2020-07-07
RU2020116419A (ru) 2021-12-27
US11110110B2 (en) 2021-09-07
US11707476B2 (en) 2023-07-25
MX2020005366A (es) 2020-08-13
UA127575C2 (uk) 2023-10-18
JP2021504345A (ja) 2021-02-15
US20190160083A1 (en) 2019-05-30
US20220257623A1 (en) 2022-08-18
EA202090987A8 (ru) 2020-09-29
IL274648A (en) 2020-06-30
EP3713933A1 (en) 2020-09-30
JP7320684B2 (ja) 2023-08-03
CN117653649A (zh) 2024-03-08
CN111386267B (zh) 2023-12-12
TW201924693A (zh) 2019-07-01
EA202090987A1 (ru) 2020-08-07
SG11202004461YA (en) 2020-06-29
MX2022016276A (es) 2023-02-09
CL2020001343A1 (es) 2020-09-25
PE20211290A1 (es) 2021-07-20
JP7443606B2 (ja) 2024-03-05
PH12020550631A1 (en) 2021-02-22
JP2023145580A (ja) 2023-10-11
JP2023055830A (ja) 2023-04-18
US20200338102A1 (en) 2020-10-29
KR20200092955A (ko) 2020-08-04
AU2018371193B2 (en) 2022-12-22
BR112019014981A2 (pt) 2020-04-07
US10729710B2 (en) 2020-08-04
CO2020006224A2 (es) 2020-05-29
JP7320507B2 (ja) 2023-08-03
AU2018371193A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
MX2022005399A (es) Compuestos.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
TN2018000299A1 (en) Heterocyclic compound.
MX2019008690A (es) Compuestos espiro heterociclicos como inhibidores de magl.
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2021007551A (es) Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas.
MX2021004085A (es) El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep).
MX2021001273A (es) Métodos para tratar trastornos neurodegenerativos.
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
EA201892640A1 (ru) Лечение болезни паркинсона